Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory

Executive Summary

Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses

You may also be interested in...



Limits Of Risk Management Practices Shown In Renewed Duragesic Warnings

FDA's approach to continued reports of deaths from fentanyl patches illustrates the challenges that the agency will face in managing drug risks even as it wields the new powers granted by the FDA Amendments Act

Limits Of Risk Management Practices Shown In Renewed Duragesic Warnings

FDA's approach to continued reports of deaths from fentanyl patches illustrates the challenges that the agency will face in managing drug risks even as it wields the new powers granted by the FDA Amendments Act

Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates

FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events

Related Content

Topics

UsernamePublicRestriction

Register

PS046076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel